Recommendations by the Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology (DCNI/ABN) and the Brazilian Committee for Treatment and Research in Multiple Sclerosis and Neuroimmunological Diseases (BCTRIMS) on vaccination in general and specifically against SARS-CoV-2 for patients with demyelinating diseases of the central nervous system

Página do item simplificado
dc.creatorJefferson Becker
dc.creatorLis Campos Ferreira
dc.creatorAlfredo Damasceno
dc.creatorDenis Bernardi Bichuetti
dc.creatorPaulo Pereira Christo
dc.creatorDagoberto Callegaro
dc.creatorMarco Aurélio Lana Peixoto
dc.creatorNise Alessandra de Carvalho Sousa
dc.creatorSérgio Monteiro de Almeida
dc.creatorTarso Adoni
dc.creatorJuliana Machado Santiago dos Santos Amaral
dc.creatorThiago de Faria Junqueira
dc.creatorSamira Luisa Apóstolos Pereira
dc.creatorAna Beatriz Ayroza Galvão Ribeiro Gomes
dc.creatorMilena Sales Pitombeira
dc.creatorRenata Barbosa Paolilo
dc.creatorAnderson Kuntz Grzesiuk
dc.creatorAna Claudia Piccolo
dc.creatorJosé Arthur Costa D´Almeida
dc.creatorAntônio Pereira Gomes Neto
dc.creatorAugusto César Penalva de Oliveira
dc.creatorBianca Etelvina Santos de Oliveira
dc.creatorCarlos Bernardo Tauil
dc.creatorClaudia Cristina Ferreira Vasconcelos
dc.creatorDamacio Ramón Kaimen Maciel
dc.creatorDaniel Lima Varela
dc.creatorDenise Sisterolli Diniz
dc.creatorEnedina Maria Lobato de Oliveira
dc.creatorFabiola Rachid Malfetano
dc.creatorFernando Elias Borges
dc.creatorFernando Faria Andrade Figueira
dc.creatorFrancisco de Assis Aquino Gondim
dc.creatorGiordani Rodrigues dos Passos
dc.creatorGuilherme Diogo Silva
dc.creatorGuilherme Sciascia do Olival
dc.creatorGutemberg Augusto Cruz dos Santos
dc.creatorHeloisa Helena Ruocco
dc.creatorHenry Koiti Sato
dc.creatorHerval Ribeiro Soares Neto
dc.creatorLeandro Cortoni Calia
dc.creatorMarcus Vinícius Magno Gonçalves
dc.creatorMaria Cecilia Aragón de Vecino
dc.creatorMaria Lucia Vellutini Pimentel
dc.creatorMarlise de Castro Ribeiro
dc.creatorMateus Boaventura de Oliveira
dc.creatorMônica Koncke Fiuza Parolin
dc.creatorRenata Brant de Souza Melo
dc.creatorRobson Lázaro
dc.creatorRodrigo Barbosa Thomaz
dc.creatorRodrigo Gonçalves Kleinpaul Vieira
dc.creatorRonaldo Maciel Dias
dc.creatorSidney Gomes
dc.creatorSimone Abrante Lucatto
dc.creatorSoniza Vieira Alves Leon
dc.creatorThiago Fukuda
dc.creatorTaysa Alexandrino Gonsalves Jubé Ribeiro
dc.creatorThereza Cristina D’ávila Winckler
dc.creatorYara Dadalti Fragoso
dc.creatorOsvaldo José Moreira do Nascimento
dc.creatorMaria Lucia Brito Ferreira
dc.creatorMaria Fernanda Mendes
dc.creatorDoralina Guimarães Brum Souza
dc.creatorFelipe von Glehn da Silva
dc.date.accessioned2023-06-21T19:57:13Z
dc.date.accessioned2025-09-08T23:41:42Z
dc.date.available2023-06-21T19:57:13Z
dc.date.issued2021-11
dc.description.abstractO DC de Neuroimunologia da ABN e o BCTRIMS trazem, nesse documento, as recomendações sobre vacinação da população com doenças desmielinizantes do sistema nervoso central (SNC) contra infecções em geral e contra o coronavírus da síndrome respiratória aguda grave 2 (SARS-CoV-2), causador da COVID-19. Destaca-se a gravidade do atual momento frente ao avanço da COVID-19 em nosso País, o que torna mais evidente e importante a criação de guia de referência para orientação aos médicos, pacientes e autoridades de saúde pública quanto à vacinação, meio efetivo e seguro no controle de determinadas doenças infecciosa. O DCNI/ABN e o BCTRIMS recomendam que os pacientes com doenças desmielinizantes do SNC (ex., EM e NMOSD) sejam constantemente monitorados, quanto a atualização do seu calendário vacinal, especialmente, no início ou antes da mudança do tratamento com uma droga modificadora de doença (DMD). É importante também salientar que as vacinas são seguras e os médicos devem estimular o seu uso em todos os pacientes. Evidentemente, deve ser dada especial atenção às vacinas com vírus vivos atenuados. Por fim, é importante que os médicos verifiquem qual DMD o paciente está em uso e quando foi feita a sua última dose, pois cada fármaco pode interagir de forma diferente com a indução da resposta imune.
dc.format.mimetypepdf
dc.identifier.doihttps://doi.org/10.1590/0004-282X-ANP-2021-0162
dc.identifier.issn1678-4227
dc.identifier.urihttps://hdl.handle.net/1843/55209
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofArquivos de Neuro-Psiquiatria
dc.rightsAcesso Aberto
dc.subjectCOVID-19 (Doença)
dc.subjectSARS-CoV-2
dc.subjectDoenças autoimunes desmielinizantes do sistema nervoso central
dc.subjectEsclerose múltipla
dc.subjectNeuromielite óptica
dc.subjectVacinação
dc.subject.otherDemyelinating autoimmune diseases, CNS
dc.subject.otherMultiple sclerosis
dc.subject.otherNeuromyelitis optica
dc.subject.otherVaccination
dc.subject.otherCOVID-19
dc.subject.otherSARS-CoV-2
dc.titleRecommendations by the Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology (DCNI/ABN) and the Brazilian Committee for Treatment and Research in Multiple Sclerosis and Neuroimmunological Diseases (BCTRIMS) on vaccination in general and specifically against SARS-CoV-2 for patients with demyelinating diseases of the central nervous system
dc.title.alternativeRecomendações do Departamento Científico de Neuroimunologia da Academia Brasileira de Neurologia (DCNI/ABN) e do Comitê Brasileiro de Tratamento e Pesquisa em Esclerose Múltipla e Doenças Neuroimunológicas (BCTRIMS) sobre vacinação em geral e contra a SARS-CoV-2 para pacientes com doenças desmielinizantes do sistema nervoso central
dc.typeArtigo de periódico
local.citation.epage1061
local.citation.issue11
local.citation.spage1049
local.citation.volume79
local.description.resumoThe Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology (DCNI/ABN) and Brazilian Committee for Treatment and Research in Multiple Sclerosis and Neuroimmunological Diseases (BCTRIMS) provide recommendations in this document for vaccination of the population with demyelinating diseases of the central nervous system (CNS) against infections in general and against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19. We emphasize the seriousness of the current situation in view of the spread of COVID-19 in our country. Therefore, reference guides on vaccination for clinicians, patients, and public health authorities are particularly important to prevent some infectious diseases. The DCNI/ABN and BCTRIMS recommend that patients with CNS demyelinating diseases (e.g., MS and NMOSD) be continually monitored for updates to their vaccination schedule, especially at the beginning or before a change in treatment with a disease modifying drug (DMD). It is also important to note that vaccines are safe, and physicians should encourage their use in all patients. Clearly, special care should be taken when live attenuated viruses are involved. Finally, it is important for physicians to verify which DMD the patient is receiving and when the last dose was taken, as each drug may affect the induction of immune response differently.
local.identifier.orcidhttps://orcid.org/0000-0002-9981-3620
local.identifier.orcidhttps://orcid.org/0000-0002-4456-2684
local.identifier.orcidhttps://orcid.org/0000-0002-7919-3989
local.identifier.orcidhttps://orcid.org/0000-0002-4011-3734
local.identifier.orcidhttps://orcid.org/0000-0003-1224-5243
local.identifier.orcidhttps://orcid.org/0000-0003-0077-173X
local.identifier.orcidhttps://orcid.org/0000-0003-2454-681X
local.identifier.orcidhttps://orcid.org/0000-0003-3185-2903
local.identifier.orcidhttps://orcid.org/0000-0001-5690-105X
local.identifier.orcidhttps://orcid.org/0000-0002-5008-2783
local.identifier.orcidhttps://orcid.org/0000-0003-1615-8008
local.identifier.orcidhttps://orcid.org/0000-0002-5679-1759
local.identifier.orcidhttps://orcid.org/0000-0003-3493-1199
local.identifier.orcidhttps://orcid.org/0000-0003-1657-6891
local.identifier.orcidhttps://orcid.org/0000-0002-3298-0264
local.identifier.orcidhttps://orcid.org/0000-0003-3548-8467
local.identifier.orcidhttps://orcid.org/0000-0002-7480-6782
local.identifier.orcidhttps://orcid.org/0000-0003-0834-1056
local.identifier.orcidhttps://orcid.org/0000-0002-6627-6515
local.identifier.orcidhttps://orcid.org/0000-0002-0755-9478
local.identifier.orcidhttps://orcid.org/0000-0002-4084-7973
local.identifier.orcidhttps://orcid.org/0000-0001-7484-3586
local.identifier.orcidhttps://orcid.org/0000-0003-1137-2398
local.identifier.orcidhttps://orcid.org/0000-0003-0833-4024
local.identifier.orcidhttps://orcid.org/0000-0002-8699-0636
local.identifier.orcidhttps://orcid.org/0000-0002-3043-1640
local.identifier.orcidhttps://orcid.org/0000-0002-3078-6804
local.identifier.orcidhttps://orcid.org/0000-0002-4939-7200
local.identifier.orcidhttps://orcid.org/0000-0002-8275-3801
local.identifier.orcidhttps://orcid.org/0000-0001-7668-0434
local.identifier.orcidhttps://orcid.org/0000-0003-3242-9007
local.identifier.orcidhttps://orcid.org/0000-0002-8957-5796
local.identifier.orcidhttps://orcid.org/0000-0002-8949-6115
local.identifier.orcidhttps://orcid.org/0000-0001-9764-3763
local.identifier.orcidhttps://orcid.org/0000-0002-2717-7522
local.identifier.orcidhttps://orcid.org/0000-0002-7333-1420
local.identifier.orcidhttps://orcid.org/0000-0001-5394-648X
local.identifier.orcidhttps://orcid.org/0000-0002-5582-1792
local.identifier.orcidhttps://orcid.org/0000-0002-1694-0457
local.identifier.orcidhttps://orcid.org/0000-0002-5758-5789
local.identifier.orcidhttps://orcid.org/0000-0002-9127-7886
local.identifier.orcidhttps://orcid.org/0000-0001-9393-6999
local.identifier.orcidhttps://orcid.org/0000-0003-3515-4061
local.identifier.orcidhttps://orcid.org/0000-0002-4402-099X
local.identifier.orcidhttps://orcid.org/0000-0002-5914-8099
local.identifier.orcidhttps://orcid.org/0000-0003-2171-8241
local.identifier.orcidhttps://orcid.org/0000-0002-6267-2940
local.identifier.orcidhttps://orcid.org/0000-0001-7537-5729
local.identifier.orcidhttps://orcid.org/0000-0002-9287-6864
local.identifier.orcidhttps://orcid.org/0000-0001-5750-6828
local.identifier.orcidhttps://orcid.org/0000-0003-3987-9596
local.identifier.orcidhttps://orcid.org/0000-0002-9744-5916
local.identifier.orcidhttps://orcid.org/0000-0002-8856-0007
local.identifier.orcidhttps://orcid.org/0000-0002-1538-6730
local.identifier.orcidhttps://orcid.org/0000-0002-7718-4288
local.identifier.orcidhttps://orcid.org/0000-0001-8202-8856
local.identifier.orcidhttps://orcid.org/0000-0003-1438-2583
local.identifier.orcidhttps://orcid.org/0000-0001-8726-089X
local.identifier.orcidhttps://orcid.org/0000-0003-3516-485X
local.identifier.orcidhttps://orcid.org/0000-0002-6136-4612
local.identifier.orcidhttps://orcid.org/0000-0003-3983-6019
local.identifier.orcidhttps://orcid.org/0000-0002-9050-3319
local.identifier.orcidhttps://orcid.org/0000-0002-1004-7641
local.publisher.countryBrasil
local.publisher.departmentHCL - HOSPITAL DAS CLINICAS
local.publisher.departmentMED - DEPARTAMENTO DE CLÍNICA MÉDICA
local.publisher.departmentMED - DEPARTAMENTO DE OFTALMOLOGIA E OTORRINOLARINGOLOGIA
local.publisher.initialsUFMG
local.url.externahttps://www.scielo.br/j/anp/a/H3kbdyFSG783FZmtyjsn3cd/?lang=en

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
Recommendations by the Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology (DCNIABN) and the Brazilian Committee for Treatment and Research in Multiple Sclerosis and Neuroimmunological Diseases.pdf
Tamanho:
160.31 KB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG